Cogstate Ltd (ASX: CGS) is an Australian neuroscience solutions company headquartered in Melbourne, Victoria, specializing in cognitive assessment technology for clinical trials, healthcare, and research. Founded in 1999, the company has established itself as a leader in digital cognitive testing, with over 2 million tests administered across 2,400+ clinical and academic trials[@cogstate].
Corporate Overview
| Attribute | Value |
|-----------|-------|
| Founded | 1999 |
| Headquarters | Melbourne, Victoria, Australia |
| Ticker | CGS (ASX) |
| CEO | Brad Fross |
| Market Cap | ~$200M AUD (2025) |
| Employees | 200+ (2025) |
| Revenue | ~$50M AUD (2025) |
Cogstate operates as a pure-play cognitive assessment company, distinguishing itself from broader eClinical solutions providers through its exclusive focus on brain health. The company's scientific-driven approach has resulted in widespread regulatory acceptance of their endpoints across major pharmaceutical markets[@cogstatea].
Business Model
Cogstate generates revenue through multiple channels:
Clinical trial services — Full-service cognitive endpoint measurement for pharmaceutical company trials
Software licensing — Cogstate Brief Battery and other tests available for licensing
Healthcare solutions — Direct-to-consumer and healthcare provider brain health monitoring
Research tools — Academic research licenses and collaborative studies
...Cogstate Ltd (ASX: CGS) is an Australian neuroscience solutions company headquartered in Melbourne, Victoria, specializing in cognitive assessment technology for clinical trials, healthcare, and research. Founded in 1999, the company has established itself as a leader in digital cognitive testing, with over 2 million tests administered across 2,400+ clinical and academic trials[@cogstate].
Corporate Overview
| Attribute | Value |
|-----------|-------|
| Founded | 1999 |
| Headquarters | Melbourne, Victoria, Australia |
| Ticker | CGS (ASX) |
| CEO | Brad Fross |
| Market Cap | ~$200M AUD (2025) |
| Employees | 200+ (2025) |
| Revenue | ~$50M AUD (2025) |
Cogstate operates as a pure-play cognitive assessment company, distinguishing itself from broader eClinical solutions providers through its exclusive focus on brain health. The company's scientific-driven approach has resulted in widespread regulatory acceptance of their endpoints across major pharmaceutical markets[@cogstatea].
Business Model
Cogstate generates revenue through multiple channels:
Clinical trial services — Full-service cognitive endpoint measurement for pharmaceutical company trials
Software licensing — Cogstate Brief Battery and other tests available for licensing
Healthcare solutions — Direct-to-consumer and healthcare provider brain health monitoring
Research tools — Academic research licenses and collaborative studiesThe company has historically derived the majority of revenue from pharmaceutical clinical trials, particularly in Alzheimer's disease and dementia, though healthcare and research segments are growing.
Cogstate Brief Battery (CBB)
The Cogstate Brief Battery is the company's flagship product, designed for rapid cognitive screening:
- 10-minute administration — Enables high-throughput screening in clinical settings
- Four core tests — Processing speed, attention, working memory, and visual learning
- Alternate forms — Multiple versions to minimize practice effects in repeated testing
- Validated cut-scores — Clinically meaningful thresholds for impairment detection[@cbb2019]
Cogstate Computerized Battery (CCB)
For more comprehensive assessment, the Computerized Battery provides:
- Extended cognitive domains coverage
- Extended duration testing (30-45 minutes)
- More granular outcome measures
- Adaptive difficulty algorithms
Cogstate Sports
Originally developed for contact sports concussion assessment, Cogstate Sports has expanded to include:
- Baseline cognitive testing
- Post-concussion monitoring
- Return-to-play protocols
- Large-scale athletic screening programs
Cogstate Register
The company's registry and monitoring platform enables:
- Longitudinal patient tracking
- Remote cognitive monitoring
- Data analytics and reporting
- Integration with electronic health records
- Validation — 105+ indications validated across diverse populations
- Global reach — Available in 111+ languages
- Regulatory clearance — FDA-cleared for clinical trial use
- Cloud infrastructure — HIPAA-compliant, GCP/ISO 27001 certified data management
- Remote testing — Web and tablet-based administration capabilities
Clinical Trial Expertise
Alzheimer's Disease and Dementia
Cogstate has extensive experience supporting Alzheimer's disease and related dementia clinical trials:
| Trial Phase | Cogstate Capabilities |
|-------------|----------------------|
| Preclinical AD | Early cognitive change detection, enrichment biomarkers |
| Prodromal/MCI | Progression tracking, sensitivity to change |
| Mild-Moderate AD | Treatment effect measurement, global cognition |
| Severe AD | Functional outcome support, caregiver measures |
The company has supported virtually every major Alzheimer's disease clinical trial over the past decade, providing cognitive endpoints for trials targeting amyloid clearance, tau reduction, neuroprotection, and symptomatic treatment.
Parkinson's Disease and Movement Disorders
Beyond Alzheimer's, Cogstate supports trials in:
- Parkinson's disease — Motor and non-motor symptom assessments
- Huntington's disease — Cognitive and behavioral measures
- Multiple sclerosis — Information processing and attention
- Stroke recovery — Rehabilitation outcome measures
- Psychiatric indications — Cognitive dimensions of depression, schizophrenia
Regulatory Acceptance
Cogstate endpoints have achieved regulatory acceptance across major markets:
| Regulatory Body | Status |
|----------------|--------|
| FDA (US) | Accepted for clinical trials, qualified endpoint |
| EMA (Europe) | Accepted for clinical trials |
| PMDA (Japan) | Accepted for clinical trials |
| TGA (Australia) | Cleared as medical device |
The company's FDA qualification of the Cogstate Brief Battery as a cognitive endpoint represents a significant competitive advantage, providing pharmaceutical sponsors with confidence in regulatory acceptance.
Competitive Landscape
Key Competitors
| Company | Strengths | Weaknesses |
|---------|-----------|------------|
| Cambridge Cognition | UK market presence, CANTAB platform | Limited FDA qualification |
| Cognivue | US healthcare focus | Smaller trial footprint |
| Neurocog Trials | CNS specialty | Smaller scale |
| Bracket (Syneos) | Full-service CRO | Less specialized |
Cogstate's competitive advantages include:
- Scientific validation — Extensive publication record and regulatory qualification
- Scale — Largest CNS-focused cognitive assessment company
- Global reach — Multilingual, multi-regional capabilities
- Regulatory expertise — Deep experience with global regulatory submissions
Key Partnerships
Pharmaceutical Alliances
Cogstate has established relationships with virtually every major pharmaceutical company engaged in CNS drug development:
- Pfizer — Longstanding partner in Alzheimer's trials
- Eli Lilly — Multiple late-stage AD trial partnerships
- Roche — Tau and amyloid program support
- Biogen — Aduhelm trial cognitive endpoints
- Merck — Multiple CNS indications
- Johnson & Johnson — Parkinson's and schizophrenia programs
Academic Collaborations
- Partnerships with leading Alzheimer's research centers
- Collaboration with academic trial networks (DIAN, A4, AXON)
- Research agreements with major universities
Healthcare Integration
- Health system partnerships for brain health screening
- Digital health platform integrations
- Telehealth cognitive assessment capabilities
Market Opportunity
Addressable Markets
Cogstate serves multiple growing markets:
CNS Clinical Trials — $3B+ global market, growing 10-15% annually
Brain Health Screening — Emerging consumer and healthcare market
Sports Concussion — Large addressable population in contact sports
Academic Research — Stable baseline with growth in neuroimaging studiesGrowth Drivers
Key market growth factors include:
- Aging population — Increasing Alzheimer's prevalence drives trial activity
- CNS pipeline growth — Record number of CNS drug candidates in development
- Digital transformation — Shift from pen-paper to digital cognitive testing
- Regulatory acceptance — Growing regulatory comfort with digital endpoints
Revenue Trends
- 2020: ~$35M AUD
- 2021: ~$38M AUD
- 2022: ~$42M AUD
- 2023: ~$45M AUD
- 2024: ~$48M AUD
- 2025: ~$50M AUD (estimated)
Revenue growth has been driven primarily by increased clinical trial activity in Alzheimer's disease, partially offset by competitive pricing pressure and R&D investment.
Capital Structure
- Listed on ASX since 2015
- No significant debt
- Conservative balance sheet supporting growth investments
Strategic Direction
Current Priorities
Clinical trial expansion — Capture share of growing CNS trial market
Healthcare market development — Build direct-to-consumer and provider channels
Technology platform enhancement — Remote testing, AI analytics
Geographic expansion — Increased US and European presenceStrategic Challenges
- Pricing pressure from larger competitors
- Dependence on Alzheimer's trial cycle
- Competition for qualified psychometricians
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Cognitive Assessment Tools](/tools/cognitive-assessment)
- [Digital Biomarkers](/topics/digital-biomarkers)
- [Clinical Trial Endpoints](/topics/clinical-trial-endpoints)
External Links
- [Cogstate Official Website](https://www.cogstate.com/)
- [ASX Announcements](https://www.asx.com.au/)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
References
[Cogstate Corporate Website](https://www.cogstate.com/)
[Cogstate Clinical Trial Solutions](https://www.cogstate.com/clinical-trials/)
[Cogstate Brief Battery validation (2019)](https://doi.org/10.1016/j.jalz.2019.01.008)
[Alzforum - Cognitive Assessment Tools](https://www.alzforum.org/)